Mission Statement, Vision, & Core Values of SOPHiA GENETICS SA (SOPH)

A company's mission and vision are more than just wall art; they are the fundamental drivers that translate into financial performance, especially for a high-growth, data-driven entity like SOPHiA GENETICS SA, which is focused on democratizing precision medicine.

You're looking at a company whose core purpose is to build a future where every patient has equal access to world-class care, and their execution is showing up in the numbers: they delivered $19.5 million in revenue in Q3 2025, a 23% year-over-year increase, and their full-year revenue guidance is now projected to be between $75 million and $77 million. How does a mission to transform patient care by expanding access to data-driven medicine globally directly translate into the 99,000 analyses performed on their SOPHiA DDM™ platform in a single quarter, and what does their 'We Care' mantra mean for their path to profitability, given a Q3 IFRS net loss of $20.0 million? Do their values create a defensible moat against competitors, or are they just aspirational?

SOPHiA GENETICS SA (SOPH) Overview

You need to know where SOPHiA GENETICS SA stands right now, and the takeaway is clear: this is a company successfully transitioning its AI-driven platform from a niche tool to a global, scalable engine for precision medicine. They are on track for a strong finish to the 2025 fiscal year, projecting revenue between $75 million and $77 million. That's a solid growth rate of 15% to 18% year-over-year, which tells you the market is defintely buying into the data-driven medicine story.

SOPHiA GENETICS was co-founded in 2011, starting as a small project at École Polytechnique Fédérale de Lausanne (EPFL) to tackle the growing data problem in genomics. Their core offering is the SOPHiA DDM™ Platform (Data-Driven Medicine), a cloud-native Software-as-a-Service (SaaS) tool that uses artificial intelligence (AI) to analyze complex multimodal data-things like genomics, radiomics (medical imaging data), and clinical information. This analysis generates actionable insights for healthcare providers and BioPharma partners working on cancer and rare diseases. Today, over 780 healthcare institutions globally use their platform to improve patient care.

• Founded: 2011 in Switzerland.
• Core Product: SOPHiA DDM™ Platform.
• Current Sales (FY 2025 Guidance): $75M to $77M.

Financial Momentum: Q3 2025 Performance

Looking at the latest Q3 2025 results, which were reported in November 2025, the company's momentum is accelerating. Revenue for the quarter hit $19.5 million, marking a significant 23% increase year-over-year. This isn't just about topline growth; it's about platform adoption. The SOPHiA DDM™ Platform performed a record 99,000 analyses in Q3 2025 alone, representing a 9% volume increase from the prior year.

The U.S. market is a major driver here. Revenue from core genomics customers in the U.S. saw a strong 30% year-over-year growth in Q3 2025. Also, the NORAM (North America) region showed a 26% year-over-year analysis volume growth, demonstrating that their expansion strategy is working. They are effectively landing new business, signing an impressive cohort of 31 new customers in Q3, with the average contract value for those new signings up a massive 180% year-over-year.

A Leader in AI-Driven Precision Medicine

SOPHiA GENETICS isn't just a software vendor; they are positioned as a global leader in AI-driven precision medicine. Their cloud-native platform is what makes them stand out, allowing healthcare institutions to break down data silos and use collective intelligence to inform patient diagnosis and treatment. They are essentially democratizing data-driven medicine, making advanced analysis accessible to a broad network of labs and hospitals.

Their success hinges on the SOPHiA DDM™ platform's ability to analyze data with high accuracy and scale across different data types and diseases, from oncology to rare disorders. This is the kind of technological moat that matters in this space. If you want to dive deeper into who is betting on this success and why, you should read Exploring SOPHiA GENETICS SA (SOPH) Investor Profile: Who's Buying and Why?

SOPHiA GENETICS SA (SOPH) Mission Statement

You need to know what drives SOPHiA GENETICS SA beyond the financials, and their mission statement is the clearest roadmap for their long-term value. The core takeaway is this: SOPHiA GENETICS is committed to turning complex biological data into simple, actionable insights for clinicians globally, which is the only way to scale precision medicine. This mission is the engine behind their projected full-year 2025 revenue of between $75 million and $77 million, a growth story built on democratizing data.

A mission statement isn't just a marketing line; it's the filter for every capital expenditure and strategic partnership. SOPHiA GENETICS's mission is: SOPHiA GENETICS SA (SOPH): History, Ownership, Mission, How It Works & Makes Money. It's a powerful, two-part declaration: to transform patient care by expanding access to data-driven medicine globally. Join us as we democratize data-driven medicine, together. This statement clearly outlines the 'what,' 'how,' and 'why' of their business model, which is why it's so critical for investors and partners to understand.

Here's the quick math: if their cloud-native platform, SOPHiA DDM™, can continue to improve its adjusted gross margin-which hit 73.1% in Q3 2025-it means the model is scalable, and the mission is working.

Component 1: Transforming Patient Care

The first, and most empathetic, component is the commitment to transforming patient care. This isn't about selling software; it's about radically improving outcomes for patients facing complex diseases like cancer and rare inherited disorders. The company's vision, 'to build a future in which each patient has equal access to world-class care,' is the ultimate expression of this goal.

This transformation is grounded in clinical reality. By March 2025, the SOPHiA DDM™ Platform had analyzed more than two million cumulative patient genomic profiles. That massive dataset is what allows their Artificial Intelligence (AI) to generate clinically actionable insights, helping a doctor in a smaller community hospital make a treatment decision with the same intelligence available at a major U.S. academic center. This is defintely a high-stakes, high-reward business.

• Improve diagnosis speed for rare diseases.
• Personalize cancer treatment with precision data.
• Enable clinical trials with rich, real-world evidence.

Component 2: Expanding Access and Democratization

The second core element-expanding access and democratizing data-driven medicine-is the company's operational strategy. Data-driven medicine (or precision medicine) used to be siloed in a few elite institutions. SOPHiA GENETICS broke that silo with a cloud-based Software-as-a-Service (SaaS) platform. This is the 'how' of their mission.

The numbers show this expansion is accelerating. As of September 30, 2025, the company had reached 488 core genomics customers, a steady increase that reflects their global reach. The platform is currently used by around 800 healthcare institutions across 72 countries, proving their ability to scale across different regulatory and healthcare systems. In Q3 2025 alone, they landed 31 new customers, with the average contract value of new signings up a staggering 180% year-over-year, which tells you they are winning bigger accounts.

Component 3: Data-Driven Medicine, Together

The final component, 'data-driven medicine, together,' speaks to their collaborative model and the power of collective intelligence. The platform doesn't just analyze data; it connects a global community of users who share and learn from anonymized insights, creating a network effect. This is the 'together' part.

This collective intelligence is the true moat around the business. For example, in Q3 2025, SOPHiA DDM™ performed a record 99,000 analyses, and this volume of data continuously refines the underlying AI algorithms. This constant feedback loop means every new analysis makes the platform smarter for all users. The partnership with AstraZeneca, a major multi-year AI breast cancer collaboration signed in 2025, is a concrete example of how the platform's network and data are being leveraged by BioPharma to accelerate drug development.

SOPHiA GENETICS SA (SOPH) Vision Statement

You're looking for the foundational beliefs driving SOPHiA GENETICS SA, and the core takeaway is simple: their vision isn't just about AI; it's a moral imperative to fix a massive healthcare inequality. Their vision is clear: 'to build a future in which each patient has equal access to world-class care.' This isn't a vague aspiration; it's a commitment to decentralizing precision medicine, ensuring that a specialist's insight isn't limited to a handful of major medical centers.

This vision is the engine behind their growth. It's why their SOPHiA DDM™ platform has analyzed over 2 million cumulative genomic profiles since its inception, effectively creating one of the largest collective intelligence networks in the world for cancer and rare disorders. That scale is how you move from an exclusive service to a democratized utility. Honestly, a vision this ambitious requires massive data volume to be defintely credible.

Mission: Democratizing Data-Driven Medicine

The company's mission statement is the action plan for their vision: 'to transform patient care by expanding access to data-driven medicine globally. Join us as we democratize data-driven medicine, together.' This means putting the power of complex genomic and multimodal data analysis directly into the hands of local healthcare providers. It's a direct challenge to the traditional, siloed model of specialty care.

Here's the quick math on their execution: In the third quarter of 2025 alone, the SOPHiA DDM™ platform performed a record 99,000 analyses, showing a 9% year-over-year volume growth. This operational metric is the real proof of their mission's success-more analyses means more patients, across more geographies, are getting data-driven insights. They reached 488 core genomics customers as of September 30, 2025, which is a tangible increase in the number of institutions they are empowering. You can read more about how this platform works and its impact on their business model here: SOPHiA GENETICS SA (SOPH): History, Ownership, Mission, How It Works & Makes Money.

Core Value in Action: The 'We Care' Mandate

While formal core values can sometimes feel like corporate boilerplate, SOPHiA GENETICS distills their ethos into a simple, powerful mantra: 'We Care.' This is the human layer on top of the AI and the data. It's what guides the decision to invest in markets that are often underserved, like their strong growth in the Asia-Pacific (APAC) and North America (NORAM) regions, which saw 35% and 26% year-over-year analysis volume growth, respectively, in Q3 2025.

This empathetic, patient-first approach is also what drives their financial strategy. The company is on a path to profitable growth, expecting to approach adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) breakeven by the end of 2026. Their full-year 2025 revenue guidance was recently increased to a range of $75 to $77 million, representing a solid 15% to 18% year-over-year growth. What this estimate hides is the fact that their average contract value for new signings increased by 180% year-over-year in Q3 2025, indicating that 'We Care' is also translating into winning larger, more valuable accounts. They are growing revenue while improving their adjusted gross margin, which hit 73.1% in Q3 2025, showing they can scale the platform efficiently while keeping the patient at the center.

SOPHiA GENETICS SA (SOPH) Core Values

You're looking past the Q3 revenue of $19.5 million and the projected full-year revenue of $75 million to $77 million for SOPHiA GENETICS SA, and that's smart. The real long-term anchor for a high-growth, AI-driven company isn't just the top line; it's the core values that drive the platform's utility and network effect. For SOPHiA GENETICS, these values map directly to their mission to expand access to data-driven medicine globally, which is defintely a high bar.

The company's vision is simple but powerful: a future where every patient gets equal access to world-class care. To get there, they lean on a few non-negotiable principles that dictate their product development, partnerships, and financial strategy. Here's how they translate their core values-Democratization, Precision, and Collaboration-into tangible 2025 actions.

Democratization and Access

This value is the engine of the company's mission, focusing on breaking down the barriers that keep advanced genomic and multimodal data analysis locked up in a few elite institutions. You see this in their 'cloud-native' approach, which makes the SOPHiA DDM™ platform accessible to a global network of hospitals and laboratories, not just the largest ones.

The proof is in the numbers for 2025. In Q3 alone, SOPHiA GENETICS signed 31 new customers, which shows they are successfully expanding the network's reach. Also, the company's focus on the underpenetrated U.S. market paid off, with revenue from core genomics customers in that region growing over 30% in Q1 2025. That's how you democratize medicine-by making the technology easy to use and widely available.

• Performed 99,000 analyses on SOPHiA DDM™ in Q3 2025.
• Reached 488 core genomics customers as of September 30, 2025.
• Signed new customers across geographies like the Nice University Hospital in France and Clinica MEDS in Chile.

Precision and Quality

In the world of precision medicine, a small error can have massive consequences, so the core value of precision is critical. SOPHiA GENETICS explicitly links high standards for their employees and governance to the values of quality, precision, and robustness. Their technology, which analyzes complex genomic and multimodal data, must deliver real-time, actionable insights, or the whole system fails.

The financial discipline and platform efficiency in 2025 reflect this value. For example, the adjusted gross margin hit 73.1% in Q3 2025. Here's the quick math: a high, consistent gross margin like that suggests the platform (SOPHiA DDM™) is highly scalable and efficient at processing the data, meaning its core function is robust and optimized. They are extracting maximum value from every dataset, which is a form of precision in resource management. For a deeper dive into the mechanics of their platform, you should read SOPHiA GENETICS SA (SOPH): History, Ownership, Mission, How It Works & Makes Money.

Collaboration and Network

The company believes that breakthroughs happen when data silos are broken, which is why collaboration is a foundational value. Their platform is designed to connect a global network of hospitals, laboratories, and biopharma institutions, creating a collective intelligence model. This network effect is what makes the AI smarter and the insights more valuable for everyone.

In 2025, SOPHiA GENETICS demonstrated this value with a major, multi-year AI breast cancer partnership with AstraZeneca, signed in Q2. This isn't just a contract; it's a deep collaboration that leverages the company's network and AI capabilities for drug development. Plus, they are continuing to win larger accounts, with the average contract value of new signings up a massive 180% year-over-year in Q3 2025. That jump in contract size shows that partners are seeing the significant value of joining and contributing to the collective network.

• Announced a partnership with Complete Genomics in November 2025 to integrate sequencing and AI analytics.
• Signed a multi-year AI breast cancer partnership with AstraZeneca in Q2 2025.
• Hit a platform milestone of passing 2 million cumulative genomic profiles analyzed since inception in Q1 2025.

What this estimate hides is the long sales cycle in healthcare, but still, the commitment to these three values-Democratization, Precision, and Collaboration-is what fuels their growth and positions them as a leader in AI-driven precision medicine.